News

The launch of three drug discovery institutes at the University of Cambridge, University of Oxford and University College London (UCL) will see 90 new research scientists recruited over

Banzel is a triazole derivative, which is structurally unrelated to currently marketed antiepileptic drugs. Earlier, the FDA had approved Banzel as adjunctive treatment of seizures associated with LGS

Inflectra is a chimeric human murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF alpha but not to lymphotoxin a (TNF

BXQ-350 is a nanovesicle formulation of Saposin C (sphingolipid activator protein C) and the phospholipid dioleoylphosphatidylserine (DOPS). Earlier, the company secured a Phase II Bridge Award (Small Business

The company has reported that ONS-3010 met the primary endpoints in its first-in-human study, which was conducted by the Centre for Human Drug Research (CHDR) in Leiden, The

ZYAN1 is an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being developed to increase the natural production of erythropoietin (EPO) as well as the efficacy of injectable EPO

The launch follows a decision from the US District Court for the District of New Jersey that US Patent No. 7,524,834 is invalid, and AstraZeneca’s request for a

The approval was based on data from a multicenter, randomized, double-blind, placebo-controlled Phase III SELECT trial. A total of 392 patients were included in the trial, in which

Erbitux is a highly active IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Merck has already positioned Japan as its regional Research and Development hub